Wyeth Licenses Hedgehog Technology for Nervous Disorders
Business Review Editor
Abstract
Curis licensed its small molecule Hedgehog pathway agonists to Wyeth Pharmaceuticals for the treatment of neurological disorders, including Parkinson’s disease and stroke. The deal is valued at US$170 M.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.